Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 7—July 2011
Dispatch

Melioidosis, Phnom Penh, Cambodia

Erika VliegheComments to Author , Lim Kruy, Birgit De Smet, Chun Kham, Chhun Heng Veng, Thong Phe, Olivier Koole, Sopheak Thai, Lut Lynen, and Jan Jacobs
Author affiliations: Author affiliations: Institute of Tropical Medicine, Antwerp, Belgium (E. Vlieghe, B. DeSmet, O. Koole, L. Lynen, J. Jacobs); Sihanouk Hospital Centre of Hope Phnom Penh, Cambodia (L. Kruy, C. Kham, C.H. Veng, T. Phe, S. Thai)

Main Article

Table 1

MICs for 54 Burkholderia pseudomallei isolates, Phnom Penh, Cambodia, July 1, 2007–January 31, 2010*

Antimicrobial drug MIC, µg/mL
MIC50 MIC90 Breakpoints, µg/mL
0.38 0.5 0.75 1 1.5 2 3 4 6 8 S R
Meropenem 3 29 16 1 3 2 0.5 1.5 <4 >16
Doxycycline† 13 19 18 3 1 0.75 1 <4 >16
Ceftazidime† 2 0 18 25 7 2 1.5 2 <8 >32
Amoxicillin/ clavulanic acid 1 0 13 30 7 2 1 1.5 2 <8 >32
Chloramphenicol



1
1
0
17
16
12



6 8 <8 >32
0.032
0.038
0.047
0.064
0.094
0.125
0.19
0.25
0.38
0.75
1
1.5
3
Sulfamethoxazole/ trimethoprim 3 1 7 12 5 9 4 7 1 1 3 1 0 0.125 0.75 <2 >4

*MICs determined by Etest (AB Biodisk, Solna, Sweden). MIC50, MIC for 50% of isolates; MIC90, MIC for 90% of isolates; S, susceptible; R, resistant; –, no isolates with this MIC.
†53 isolates included.

Main Article

Page created: August 15, 2011
Page updated: August 15, 2011
Page reviewed: August 15, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external